Frontier Pharma : Pain – Identifying and Commercializing First-in-Class Innovation – Acute Market Reports

Frontier Pharma: Pain – Identifying and Commercializing First-in-Class Innovation

Browse Full Report Visit :-


Large and Innovative Pipeline

The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation. This is in stark contrast to the pain therapeutics market, which has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and the concomitant mechanisms of action. Moderate-to-severe pain continues to be dominated by opioids that are increasingly being reformulated to offer abuse-resistance, while mild pain is effectively treated with Non-Steroidal Anti-Inflammatory Drugs (NSAID). However, significant unmet needs remain, as chronic pain and some neuropathic pain subtypes do not respond well to existing therapies, which are not adequate to treat associated hypersensitization and do not align to the underlying molecular pathophysiological profile.

Despite being mostly distributed in the early stages of development, first-in-class innovation is particularly concentrated on novel molecular targets that are aligned to the central sensitization associated with neuropathic pain, which is arguably the most debilitating and difficult-to-treat type of chronic pain. This gives them the potential to transform the future market by expanding the range of drug classes.


The report covers and includes –

– A brief introduction to pain, including the different subtypes of pain, pathophysiology, and overview of pharmacotherapy and treatment algorithms

– The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline


Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to –

– Understand the focal shifts in molecular targets in the pain therapeutics pipeline

– Understand the distribution of pipeline programs by phase of development, molecule type and molecular target

– Access a scientific and clinical analysis of first-in-class developmental programs for pain, benchmarked against non-first-in-class targets.

Browse All Reports of This Category :-

1 Table of Contents 2
1.1 List of Figures 3

2 Executive Summary 4
2.1 Large and Innovative Pipeline 4
2.2 Highly Diversified Range of Innovative Programs in Early Pipeline and in Granted Patents 4
2.3 Active Deals landscape with Numerous Investment Oppertunities 4

3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Development Remains Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 9

4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.1.1 Chronic and Neuropathic Pain 10
4.1.2 Disease Pathophysiology 11

To Get Complete Report @

About Us:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the worlds most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Contact Us :

Name : Chris Paul


Designation : Global Sales Manager

Toll Free(US/CANADA): +1-855-455-8662

Email :

Website :